Abstract
Valepotriates are epoxide-bearing triesters of the monoterpene alcohol 4,7-dimethylcyclopenta-(c)-pyrane isolated from the roots of several Valerianacae species. They are regarded as the main tranquilizing constituents of these drugs.
Although the valepotriates valtrate/isovaltrate (VAL) and dihydrovaltrate (DH-VAL) showed a strong alkylating activity against the nucleophilic agent 4-(p-nitrobenzyl)-pyridine (NBP), they were not clearly mutagenic for the strains TA98, TA100, TA1535, and TA1537 of Salmonella typhimurium or for the strains WP2 and WP2 uvrA− of Escherichia coli in the absence of a metabolic activation system (S9-mix). However, the valepotriates were mutagenic for TA100, WP2 and WP2 uvrA− at concentrations up to about 1.0 μmole/plate when S9-mix was added to the test system. With more than 1 μmole/plate the valepotriates were toxic in the presence of a metabolic activation system for all strains tested. The mutagenicity of the valepotriates was inversely related to the protein content of the S9-mix used. The mutagenicity and toxicity of the valepotriates could be inhibited when the S9-mix was preincubated with the esterase inhibitor paraoxon (1 mM) for 5 min before the test compounds and bacteria were added. Therefore, bioactivation of the valepotriates by an enzymatic hydrolysis of their ester groups is considered. This could be proven by activating the valepotriates with purified esterase.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ames BN, McCann J, Yamasaki E (1975) Methods for detecting carcinogens and mutagens with the Salmonella mammalian microsome mutagenicity test. Mutat Res 31: 347–364
Aukermann SL, Brundrett RB, Hilton J, Hartmann PhE (1983) Effect of plasma and carboxylesterase on the stability, mutagenicity, and DNA cross-linking activity of some direct-acting N-nitroso-com-pounds. Cancer Res 43: 175–181
Barbin A, Brisil H, Croisy A, Jacquignon P, Malaveille C, Montesano R, Bartsch H (1975) Liver-microsome-mediated formation of alkylating agents from bromide and vinyl chloride. Biochem Biophys Res Commun 67: 596–603
Boeters U (1969) Behandlung vegetativer Regulationsstörungen mit Valepotriaten (ValmaneR). Münch Med Wschr 111: 1873–1876
Bos RP, Brouns RME, van Doorn R, Theuws JLG, Henderson PTh (1981) Involvement of non-oxidative enzymes in mutagenic activation of urine from rats, given benzidine and some other aromatic amines. Toxicology 21: 223–233
Bountanh C, Bergmann C, Beck JP, Haag-Berrurier M, Anton R (1981) Valepotriates, a new class of cytotoxic and antitumor agents. Planta Med 41: 21–28
Bountanh C, Richert L, Beck JP, Haag-Berrurier M, Anton R (1983) The action of valepotriates on the synthesis of DNA and proteins of cultured hepatoma cells. Planta Med 49: 138–142
Braun R, Dittmar W, Machut M, Weickmann S (1982) Valepotriate mit Epoxidstruktur — beachtlich'e Alkylantien. Dtsch Apth Z 122: 1109–1113
Dossaji SF, Becker H (1981) HPCL separation and quantitative determination of valepotriates from Valeriana kilimandascharica. Planta Med 43: 179–183
Eder E, Neudecker T, Lutz D, Henschler D (1982a) Correlation of alkylating and mutagenic activities of allyl and allylic compounds: standard alkylation test vs. kinetic investigation. Chem Biol Interact 38: 303–315
Eder E, Henschler D, Neudecker T (1982b) Mutagenic properties of allylic and α, β-unsaturated compounds: consideration of alkylating mechanismus. Xenobiotica 12: 831–848
Eickstedt von KW, Rahman S (1969) Psychopharmakologische Wirkungen von Valepotriaten. Arzneim Forsch 19: 316–319
El-Tantawy MA, Hammock BD (1980) The effect of hepatic microsomal and cytosolic subcellular fractions on the mutagenic activity of epoxide-containing compounds in the salmonella assay. Mutat Res 79: 59–71
Esterbauer HA, Ertl A, Scholz N (1976) The reaction of cysteine with α,β-unsaturated aldehydes. Tetrahedron 32: 285–289
Fu PP, Heflich RH, Casciano DA, Huang AY, Trie WM, Kadlubar FF, Beland FA (1982) Biologically active aromatic amines derived from carcinogenic polycyclic aromatic hydrocarbons: synthesis and mutagenicity of amino[a]pyrenes. Mutat Res 94: 13–21
Glatt H, Jung R, Oesch F (1983) Bacterial mutagenicity investigation of epoxides: drugs, drug metabolites, steroids and pesticides. Mutat Res 111: 99–118
Hemminki K, Falck K (1979) Correlation of mutagenicity and 4-(p-nitrobenzyl)-pyridine alkylation by epoxides. Toxicol Lett 4: 103–106
Holm E, Kowollik H, Reinecke A, Henning von GE, Behne F, Scherer H-D (1980) Vergleichende neurophysiologische Untersuchungen mit Valtratum/Isovaltratum und Extractum Valerianae an Katzen. Med Welt 31: 982–990
Jansen W (1977) Doppelblindstudie mit Baldrisedon. Therapiewoche 27: 2779–2786
Kaneda S, Seno T, Takeishi K (1981) Species differences in liver microsomal and cytosolic enzymes involved in mutagenic activation of N-hydroxy-N-2-fluorenylacetamide. J Natl Cancer Inst 67: 549–555
Krueger GAW (1969) Die Therapie des psychovegetativen Syndroms mit ValmaneR. Therapiewoche 19: 89–94
Lutz D, Eder E, Neudecker T, Henschler D (1982) Structure mutagenicity relationship in α,β-unsaturated carbonylic compounds and their corresponding allylic alcohols. Mutat Res 93: 305–315
Maron DM, Ames BN (1983) Revised methods for the Salmonella mutagenicity test. Mutat Res 113: 173–215
Mayer B, Springer E (1974) Psychoexperimentelle Untersuchungen zur Wirkung einer Valepotriatkombination sowie zur kombinierten Wirkung von Valtratum und Alkohol. Arzneim Forsch 24: 2066–2070
Oesch F, Glatt HR (1976) Evaluation of the importance of enzymes involved in the control of mutagenic metabolites. In: Montesano R, Bartsch H, Tomatis L (eds) Screening tests in chemical carcinogenesis. IARC, Lyon, pp 255–274
Rossi AM, Migliore L, Loprieno N, Romano M, Salmona M (1983) Evaluation of epichlorohydrin (ECH) genotoxicity. Microsomal epoxide hydrolase-dependent deactivation of ECH mutagenicity in Schizosaccharomyces pombe in vitro. Mutat Res 109: 41–52
Shauenstein E, Esterbauer H, Zollner U (1977) Aldehydes in biological systems, their natural occurence and biological activities. Pion Limited, London
Spassow N, Gürowa-Postorino P (1980) “Tranquilizer” auf pflanzlicher Basis. Ärztl Praxis 32: 1526–1528
Staiano N, Erickson LC, Smith CL, Marsden E, Thorgeiersson SS (1983) Mutagenicity and DNA damage induced by arylamines in the Salmonella/Hepatocyte system. Carcinogenesis 4: 161–167
Thies PW (1966) Über die Wirkstoffe des Baldrians, 2. Mitteilung. Tetrahedron Lett 11: 1163–1170
Thies PW (1967) Zur Chemie der Valepotriate. Dtsch Apoth Z 107: 1411–1412
Thies PW (1969) Zum chromogenen Verhalten der Valepotriate. Arzneim Forsch 19: 319–322
Thies PW, Funke S (1966) Über die Wirkstoffe des Baldrians. 1. Mitteilung. Tetrahedron Lett 11: 1155–1162
Tortarolo M, Braun R, Hübner GE, Maurer HR (1982) In vitro effects of epoxide-bearing valepotriates on mouse early hematopoietic prognenitor cells and human T-lymphocytes. Arch Toxicol 51: 37–42
Voogd CE, van der Stel JJ, Jacobs JJJAA (1981) The mutagenic action of aliphatic epoxides. Mutat Res 89: 269–282
Wood AW, Wislocki PG, Chang RL, Levin W, Lu AYH, Yagi H, Hernandez O, Jerina DM, Conney AH (1976) Mutagenicity and cytotoxicity of benzo[a] pyrene benzo-ring epoxides. Cancer Res 36: 3358–3366
Yoshikawa K, Isobe M, Watabe F, Takabatake E (1980) Studies on metabolism and toxicity of styrene. III. The effect of metabolic inactivation by rat-liver S9 on the mutagenicity of phenyloxirane toward Salmonella typhimurium. Mutat Res 78: 219–226
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
von der Hude, W., Scheutwinkel-Reich, M., Braun, R. et al. In vitro mutagenicity of valepotriates. Arch Toxicol 56, 267–271 (1985). https://doi.org/10.1007/BF00295166
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00295166